GCM
DNA icon

Graham Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Graham Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Sell
11,620
-24,693
-68% -$207K ﹤0.01% 1135
2026
Q1 		$223K Sell
36,313
-51,725
-59% -$430K 0.01% 923
2025
Q4 		$732K Buy
+88,038
New +$948K 0.02% 483
2024
Q1 		– Sell
-2,644
Closed -$179K – 1118
2023
Q4 		$179K Buy
+2,644
New +$162K ﹤0.01% 856

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Graham Capital Management's DNA Position: Q2 2026 in Review

Graham Capital Management reduced its Ginkgo Bioworks (DNA) stake by 68% in Q2 2026, selling an estimated $207K and leaving 11,620 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #1135.

Graham Capital Management first reported a position in DNA in Q4 2023 and has held it in 4 quarters since. The position peaked at $732K in Q4 2025. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Graham Capital Management held 11,620 shares of Ginkgo Bioworks worth $115K as of Q2 2026.
  • Graham Capital Management sold 24,693 Ginkgo Bioworks shares in Q2 2026, an estimated $207K.
  • Ginkgo Bioworks made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1135 holding.
  • Graham Capital Management first reported a position in Ginkgo Bioworks in Q4 2023 and has held it in 4 quarters since.
  • Graham Capital Management's Ginkgo Bioworks position peaked at $732K in Q4 2025.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.